Mainz Biomed (MYNZ)

• Market cap: $6.98M
• 1 day: -8.04%
• 5 days: -9.85%
• 1 month: -25.91%
• 3 months: -61.31%
• 6 months: -65.86%
• Year to date: -57.44%
• 1 year: -93.07%
• 5 years: -99.54%
• 10 years: -99.54%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Employees: 26

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

43% more funds holding

Funds holding: 7 [Q4 2024] → 10 (+3) [Q1 2025]

0.52% less ownership

Funds ownership: 11.05% [Q4 2024] → 10.53% (-0.52%) [Q1 2025]

29% less capital invested

Capital invested by funds: $1.06M [Q4 2024] → $750K (-$309K) [Q1 2025]

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4